IL6 and hepatocellular carcinoma: In terms of treatment application, sorafenib is suitable for HCC with the low expression of IL-6, whereas IFN-α is suitable for HCC with high IL-6 expression, which may be caused by the up-regulation of NF-kB and thereby could facilitate the IFN-α treatment as found in other studies [11].